CorNova Announces Award of ISO 13485 Certification.WAKEFIELD, Mass. -- Implant Sciences Corporation (AMEX AMEX See: American Stock Exchange : "IMX IMX In My eXperience IMX Interactive Music Exchange (TV show) IMX Integrated Multimedia Exchange IMX Industrywide Mortgage Exchange IMX Intermodal Marketing Extension IMX Inverse Multiplexor ", "IMX.WS") and CardioTech International, Inc. (AMEX: "CTE (Coefficient of Thermal Expansion) The difference between the way two materials expand when heat is applied. This is very critical when chips are mounted to printed circuit boards, because the silicon chip expands at a different rate than the plastic board. ") jointly announce that CorNova GmbH of Munich, Germany has achieved ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 13485 certification. CorNova, GmbH is a wholly-owned subsidiary of CorNova, Inc headquartered in Billerica, MA. Cardiotech and Implant Sciences, which each own approximately 18% of CorNova, Inc. on a fully-diluted basis, are working with CorNova to commercialize both the metallic as well as the drug-eluting stent for the interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based market. CorNova plans to launch its first advanced cobalt-chromium coronary stent coronary stent Intracoronary stent Cardiology An expandable tubular device which can be inserted percutaneously, and left within a coronary artery lumen to maintain its patency Pros Clinical and angiographic outcomes are better with intracoronary artery stent system in the second quarter of this calendar year. By obtaining ISO 13485 certification, CorNova will be able to sell its products throughout Europe and many other world-wide markets, excluding the United States and Japan. CorNova is in the process of establishing an additional wholly-owned subsidiary based in Argentina to facilitate distribution in Latin America. Cardiotech and CorNova are progressing with their development of a next-generation polymer system and generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. for CorNova's drug-eluting stent program. CorNova is working with CardioTech to develop a specialized polymer coating containing an anti-restenosis drug. This proprietary polymer coating is being designed to supply the optimal drug-eluting kinetics while providing the physical properties and integrity required for today's difficult interventions, including bifurcations and long-lesion stenting. S. Eric Ryan, M.D, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CorNova, said, "We are very pleased and would like to congratulate our European subsidiary, CorNova, GmbH, for achieving ISO 13485 certification. We look forward to launching our first coronary stent system in Europe and Latin America. We are also excited about our continuous progress with our advanced drug-eluting stent system and are eager to continue this development with our partners, CardioTech International and Implant Sciences." About Implant Sciences Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives which are distributed under the Quantum Sniffer(TM) brand name. The Company also provides state of the art ion implantation and wafer analytical services for the semiconductor industry. The Company also develops, manufactures and sells radioactive products for the treatment of cancer, including sales of radioactive seeds for the treatment of prostate cancer and development of a new, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved radioactive source for use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com. Implant Sciences believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the period ended June 30, 2005, and Quarterly Report on Form 10-Q for the period ended September 30, 2005. The Company assumes no obligation to update the information contained in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion